The initiative aims to educate patients and healthcare providers about the benefits and limitations of NIPT screening and how to interpret the results.
Recent cost analyses funded by Ariosa and Natera found that NIPT could replace conventional screening in the US and be cost-neutral if provided at certain prices.
The researchers identified a large set of potential markers, and then narrowed them down to those with the most practical diagnostic potential.
Chromsomal array testing had a higher diagnostic yield in the study than standard procedures, and could have value as a first step before referring patients to further tests.
The change makes Anthem one of the first major payors to say that NIPT is medically necessary for the non-high-risk pregnancy population.
The Center for Human Genetics and Laboratory Medicine's Prenatalis test is based on Illumina's Verifi technology.
Birmingham Women's NHS Foundation Trust said it is partnering with Illumina to develop an NIPT, which it hopes to start offering in September.
SeraCare is licensing UCSF's T21, T18, and T13 trophoblast cell line materials to develop NIPT reference materials.
Non-invasive prenatal screening tests are not only detecting fetal chromosomal abnormalities, but also some cases of maternal cancer.
The results are the most comprehensive picture so far of the patterns of abnormal NIPT results that could indicate a woman has a higher risk of carrying an unknown tumor.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.